Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma October 30, 2020 Publications VIEW PUBLICATIONS ⟶ Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype August 27, 2020 Publications VIEW PUBLICATIONS ⟶ Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia August 23, 2020 Publications VIEW PUBLICATIONS ⟶ Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment July 22, 2020 Publications VIEW PUBLICATIONS ⟶ Monitoring minimal residual disease in the bone marrow using next generation sequencing January 17, 2020 Publications VIEW PUBLICATIONS ⟶ Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence November 13, 2019 Publications VIEW PUBLICATIONS ⟶ Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma October 1, 2019 Publications VIEW PUBLICATIONS ⟶ Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms March 21, 2019 Publications VIEW PUBLICATIONS ⟶ A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations August 25, 2018 Publications VIEW PUBLICATIONS ⟶ Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL August 22, 2018 Publications VIEW PUBLICATIONS ⟶
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms
